Seres Therapeutics (MCRB) Competitors $11.36 +0.50 (+4.56%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$11.94 +0.58 (+5.11%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. OLMA, AURA, ATXS, ZYBT, LFCR, BNTC, AVIR, IVA, AARD, and OCGNShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Olema Pharmaceuticals (OLMA), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Zhengye Biotechnology (ZYBT), Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Its Competitors Olema Pharmaceuticals Aura Biosciences Astria Therapeutics Zhengye Biotechnology Lifecore Biomedical Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Ocugen Seres Therapeutics (NASDAQ:MCRB) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment. Do analysts recommend MCRB or OLMA? Seres Therapeutics currently has a consensus price target of $73.67, indicating a potential upside of 548.76%. Olema Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 456.82%. Given Seres Therapeutics' higher probable upside, equities analysts plainly believe Seres Therapeutics is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of MCRB or OLMA? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, MCRB or OLMA? Seres Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Does the media prefer MCRB or OLMA? In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 equaled Olema Pharmaceuticals'average media sentiment score. Company Overall Sentiment Seres Therapeutics Neutral Olema Pharmaceuticals Neutral Which has better earnings & valuation, MCRB or OLMA? Seres Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.32M0.78$140K-$4.60-2.47Olema PharmaceuticalsN/AN/A-$129.47M-$2.01-2.19 Is MCRB or OLMA more profitable? Olema Pharmaceuticals' return on equity of -42.31% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A -41,084.76% -55.87% Olema Pharmaceuticals N/A -42.31%-38.32% SummaryOlema Pharmaceuticals beats Seres Therapeutics on 9 of the 13 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.83M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-2.4721.5627.4020.24Price / Sales0.78281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book7.057.518.085.67Net Income$140K-$55.05M$3.16B$248.47M7 Day Performance24.78%4.71%2.84%3.32%1 Month Performance59.26%4.89%3.69%5.20%1 Year Performance-19.10%5.82%35.30%21.35% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.0707 of 5 stars$11.36+4.6%$73.67+548.8%-19.1%$94.83M$126.32M-2.47330OLMAOlema Pharmaceuticals1.7527 of 5 stars$4.26-7.8%$24.50+475.1%-58.8%$316.11MN/A-2.1270AURAAura Biosciences1.7459 of 5 stars$6.26-0.3%$22.00+251.4%-4.5%$315.69MN/A-3.2950ATXSAstria Therapeutics1.4564 of 5 stars$5.36-3.8%$30.00+459.7%-35.4%$314.34MN/A-2.8730News CoverageZYBTZhengye BiotechnologyN/A$5.97-9.7%N/AN/A$311.77MN/A0.00278News CoverageLockup ExpirationLFCRLifecore Biomedical1.6274 of 5 stars$8.12-0.9%$8.00-1.5%+62.9%$303.24M$128.26M-5.60690Positive NewsHigh Trading VolumeBNTCBenitec Biopharma1.732 of 5 stars$11.70+3.1%$23.83+103.7%+48.6%$297.94M$80K-7.7520Positive NewsHigh Trading VolumeAVIRAtea Pharmaceuticals2.377 of 5 stars$3.60+4.3%$6.00+66.7%+11.9%$295.25MN/A-2.1870High Trading VolumeIVAInventiva2.7926 of 5 stars$3.19+4.6%$10.40+226.0%+3.0%$291.77M$9.95M0.00100Gap UpAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018Analyst RevisionGap UpOCGNOcugen1.0207 of 5 stars$0.97-1.4%$6.00+518.3%-41.1%$287.39M$4.05M-5.1180High Trading Volume Related Companies and Tools Related Companies OLMA Competitors AURA Competitors ATXS Competitors ZYBT Competitors LFCR Competitors BNTC Competitors AVIR Competitors IVA Competitors AARD Competitors OCGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
